About Concerto Biosciences
Concerto Biosciences is a company based in Cambridge (United States) founded in 2019 by Bernardo Cervantes and Jared Kehe. Concerto Biosciences has raised $24.54 million across 2 funding rounds from investors including HHS, Safar Partners and Horizons Ventures. Concerto Biosciences offers products and services including ENS-002, CB-002, and ENS-003. Concerto Biosciences operates in a competitive market with competitors including ASLAN Pharmaceuticals, UNION Therapeutics, Biosion, Forte Biosciences and PinCell, among others.
- Headquarter Cambridge, United States
- Founders Bernardo Cervantes, Jared Kehe
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Concerto Biosciences
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.54 M (USD)
in 2 rounds
-
Latest Funding Round
$299.91 K (USD), Grant
Jul 01, 2022
-
Investors
HHS
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Concerto Biosciences
Concerto Biosciences offers a comprehensive portfolio of products and services, including ENS-002, CB-002, and ENS-003.
Microbiome-based treatment for atopic dermatitis conditions.
Product for achieving calm and balanced skin health.
Microbiome solution for vaginal yeast infection management.
People of Concerto Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Concerto Biosciences
Concerto Biosciences has successfully raised a total of $24.54M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $299.91 thousand completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Concerto Biosciences
Concerto Biosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Safar Partners and Horizons Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Safar Partners is engaged in investing in technology startups.
|
Locked | Locked | Locked | |
|
Horizons Ventures is focused on investing in deep science and technology.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for Concerto Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Concerto Biosciences
Investment portfolio details for Concerto Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Concerto Biosciences
Detailed financials for Concerto Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Concerto Biosciences Comparisons
Peer comparison for Concerto Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Concerto Biosciences
Concerto Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ASLAN Pharmaceuticals, UNION Therapeutics, Biosion, Forte Biosciences and PinCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted small molecules are developed for oncology treatments.
|
|
| Locked | Locked | Locked |
Small molecule antibiotics are developed for bacterial infections.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of anti-inflammatory therapy for the treatment skin diseases
|
Detailed competitors of Concerto Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Concerto Biosciences
Complete news archive for Concerto Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concerto Biosciences
Concerto Biosciences was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Concerto Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Concerto Biosciences is a funded company, having raised a total of $24.54M across 2 funding rounds to date.
Founded in 2019 and based in Cambridge, United States, Concerto Biosciences operates in the biotechnology sector. Microbe-based solutions are created for applications in agriculture and human health. A lead product, ENS-002, is offered, consisting of microbes that restore skin microbiome balance and reduce S. aureus virulence to address eczema. Operations focus on rehabilitating protective microbial interactions.
Concerto Biosciences's top competitors include ASLAN Pharmaceuticals, UNION Therapeutics and Biosion.
Concerto Biosciences offers ENS-002, CB-002, and ENS-003.
Concerto Biosciences has 5 investors. Key investors include HHS, Safar Partners, Horizons Ventures, M-Ventures, and Corundum Systems Biology.